摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-cyclopentyl-1H-pyrrole-2-carbaldehyde

中文名称
——
中文别名
——
英文名称
1-cyclopentyl-1H-pyrrole-2-carbaldehyde
英文别名
1-cyclopentylpyrrole-2-carbaldehyde
1-cyclopentyl-1H-pyrrole-2-carbaldehyde化学式
CAS
——
化学式
C10H13NO
mdl
MFCD09674979
分子量
163.219
InChiKey
BGODSQVXIILUQC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    22
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

点击查看最新优质反应信息

文献信息

  • One-Pot Amberlyst 15-Controlled Cyclocondensation of Piperidines and Arylaldehydes: Synthesis of 3,5-Diarylmethylpyridines
    作者:Meng-Yang Chang、Yu-Lin Tsai
    DOI:10.1021/acs.joc.9b03315
    日期:2020.4.17
    Amberlyst 15-controlled one-pot easy-operational intermolecular cyclocondensation of substituted piperidines with arylaldehydes provides diversified 3,5-diarylmethylpyridines in high to excellent yields under refluxing toluene conditions. The uses of various acidic solid supports and reaction solvents are investigated for facile and efficient transformation. A plausible mechanism has been proposed
    在芳基醛回流下,Amberlyst 15受控的一锅式易操作的哌啶与芳醛的分子间环缩合反应提供了多样化的3,5-二芳基甲基吡啶。研究了各种酸性固体载体和反应溶剂的使用,以实现简便高效的转化。已经提出了一种合理的机制。
  • HETEROCYCLIC COMPOUND
    申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
    公开号:US20150141406A1
    公开(公告)日:2015-05-21
    The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种具有优异的JAK抑制作用的化合物,可用作自身免疫性疾病(类风湿性关节炎、屑病、炎症性肠病、干燥综合征、Behcet病、多发性硬化症、系统性红斑狼疮等)、癌症(白血病、子宫平滑肌肉肉瘤、前列腺癌、多发性骨髓瘤、消瘦、骨髓纤维化等)等的预防或治疗剂,或其盐。本发明涉及一个由公式表示的化合物,其中每个符号如规范中所定义,或其盐。
  • Heterocyclic compound
    申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
    公开号:US09371320B2
    公开(公告)日:2016-06-21
    The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种具有优异的JAK抑制作用的化合物,可用作自身免疫性疾病(类风湿性关节炎、牛皮癣、炎症性肠病、Sjogren综合症、Behcet病、多发性硬化症、系统性红斑狼疮等)、癌症(白血病、子宫平滑肌肉肉瘤、前列腺癌、多发性骨髓瘤、消耗症、骨髓纤维化等)等的预防或治疗剂,或其盐。本发明涉及一种由式中各符号如规范中所定义的化合物,或其盐。
  • US9371320B2
    申请人:——
    公开号:US9371320B2
    公开(公告)日:2016-06-21
查看更多